glp 1 inhibitors moa Mechanism of action of GLP-1 [25] Mechanisms of dipeptidyl peptidase‐4 (DPP‐4)

The present case study examines a rare case of MNTI in the right mandible and its subsequent treatment

The rapid rise of GLP-1 drugs, however, has also prompted broader public health and ethical discussions

Seven additional Phase 3 trials for retatrutide are expected to report results in 2026

TNF-, IL-6, IL-1 that trigger disruptions in synaptic remodeling, brain connectivity and network function

These symptoms can range from mild to severe and significantly impact quality of life

To reach a more rapid and stable improvement, this psychologically devastating disorder should be treated with a multimodality approach that incorporates photoprotective agents, antioxidant treatments, skin lighteners, exfoliants